Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% each
Unlock Stocks
4.40
-0.02
-0.45%
13/11 - Closed. Currency in GBP
- Morningstar Rating:
- Total Assets: 585.46M
AXA Framlington Health Fund Z GBP Acc
4.40
-0.02
-0.45%
- Overview
- Profile
- Historical Data
- Holdings
Axa Framlington Health Fund Z Acc Overview
On this page you'll find an in-depth profile of Axa Framlington Health Fund Z Acc. Learn about the key management, total assets, investment strategy and contact information of 0P0000XMSV among other information.
Investment Strategy
The aim of this Fund is to provide long-term capital growth over a period of 5 years or more. The Fund invests in shares of listed healthcare companies including producers of pharmaceuticals, biotechnology firms, medical device and instrument manufacturers, distributors of healthcare products, care providers and managers and other healthcare services companies, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world albeit the Fund tends to be biased towards the US, as this is where the majority of healthcare related companies are based. The Manager selects shares based upon analysis of a company’s financial status, quality of its management, expected profitability and prospects for growth.
Contact Information
Address
100, Esplanade du Général de Gaulle
Paris, 92932
France
Paris, 92932
France
Phone
+33 1 44 45 70 00
Fax
Paris
Top Executives
| Name | Title | Since | Until |
|---|---|---|---|
| Catherine Tennyson | - | 2024 | Now |
| Chris Eccles | Research Analyst | 2024 | Now |
| Biography | Chris Eccles is a research analyst who specialises in testing and regulatory affairs. He researches stocks globally and focuses on the Healthcare sector. Chris joined Impax in March 2019. He started working in the financial industry in 2011 as a research analyst at Morgan Stanley where he focused on European large-cap pharmaceuticals. In 2014, he became a partner at the hedge fund Kola Capital where he worked as a global equities analyst for three years before moving to Stifel in 2017 to work as a Healthcare Specialist. Chris achieved an MA (Oxon) Physiological Sciences First Class Honours, from the University of Oxford. | ||
| Cinney Zhang | - | 2023 | Now |
| Linden Thomson | - | 1987 | 2024 |
| Peter Hughes | Portfolio Manager | 2021 | 2023 |
| Biography | Peter joined Redwheel in July 2023 as a Partner and Portfolio Manager. He will manage the Redwheel Life Changing Treatments strategy. His ambition for the role is to focus on improving patients’ lives, regardless of where they live by investing in companies facilitating improved health care outcomes while providing long-term capital appreciation for investors. Before Redwheel, Peter was Portfolio Manager of the AXA World Funds Longevity Economy fund and AXA Framlington Health fund, specialising in healthcare. Before this, he held appointments at Architas, in roles covering investment research and relationship management. Peter holds a PhD in biochemistry from University College London. He has a master's degree in chemistry from the University of Surrey and is a CFA Charterholder. He is also an ambassador for the Royal Marsden Cancer Charity. Peter was named as a 2021 Rising Star of Asset Management by Financial News. | ||
| Dani Saurymper | - | 2015 | 2021 |
| Biography | Dani Saurymper joined AXA IM in April 2015 as Fund Manager for the AXA Framlington Health Fund. He joined from Barclays Capital where he was a senior equity research analyst covering European healthcare. | ||
| Mark Hargraves | Portfolio Manager | 2014 | 2016 |
| Biography | Mark attended the University of Bristol gaining a Geography BSc (Hons). In 2000, he obtained a Masters in Finance from the London Business School. He is also a member of the UK Society of Investment Professionals. Mark spent two years working for Abbey National plc and then moved to Hambros Fund Management as assistant portfolio manager European Equities. In 1997, he joined United Friendly Asset Management as a fund manager for European Equities. Mark joined AXA Framlington as a fund manager in June 2000. | ||
| Gemma Game | - | 2011 | 2014 |
| Deane Donnigan | clinical Specialist | 1997 | 2011 |
| Biography | Deane joined Polar Capital in June 2013 as a senior analyst for the Healthcare team and has over 34 years’ industry experience, including over 15 years within healthcare asset management. She trained as a clinical pharmacist, graduating with a post baccalaureate Doctor of Pharmacy from the University of Georgia. Deane began her career at the Medical College of Georgia, before becoming a clinical specialist in Drug Information and Adult Internal Medicine with Emory University Hospital in Atlanta, Georgia. After several years, she moved to the UK to join Framlington (now AXA Framlington) applying her extensive pharmaceutical expertise working as an analyst for the healthcare unit trust, led by Anthony Milford. She went on to become lead portfolio manager of the Framlington Healthcare and Framlington Biotechnology funds. Deane is both a US and UK citizen. | ||
| Antony Milford | - | 1987 | 2007 |
Write your thoughts about Axa Framlington Health Fund Z Acc
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review